Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127866511 | 12786651 | 1 | I | 20160921 | 20160927 | 20160927 | PER | US-ASTRAZENECA-2016SF01961 | ASTRAZENECA | 0.00 | F | Y | 81.60000 | KG | 20160927 | CN | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127866511 | 12786651 | 1 | SS | ATENOLOL. | ATENOLOL | 1 | Oral | 0 | 50 | MG | TID | ||||||||
| 127866511 | 12786651 | 2 | PS | NEXIUM | ESOMEPRAZOLE MAGNESIUM | 1 | Oral | DAILY | U | 21153 | CAPSULE | ||||||||
| 127866511 | 12786651 | 3 | SS | NEXIUM | ESOMEPRAZOLE MAGNESIUM | 1 | Oral | 0 | 20 | MG | QD | ||||||||
| 127866511 | 12786651 | 4 | SS | BYDUREON | EXENATIDE | 1 | Subcutaneous | 0 | 2 | MG | /wk | ||||||||
| 127866511 | 12786651 | 5 | SS | BYDUREON | EXENATIDE | 1 | Subcutaneous | 0 | |||||||||||
| 127866511 | 12786651 | 6 | C | NOVOLOG | INSULIN ASPART | 1 | Unknown | 0 | BID | ||||||||||
| 127866511 | 12786651 | 7 | C | FUROSEMIDE. | FUROSEMIDE | 1 | Oral | 0 | 20 | MG | QD | ||||||||
| 127866511 | 12786651 | 8 | C | HYDROXYZINE | HYDROXYZINEHYDROXYZINE HYDROCHLORIDE | 1 | Oral | 0 | 25 | MG | QD | ||||||||
| 127866511 | 12786651 | 9 | C | METFORMIN | METFORMIN HYDROCHLORIDE | 1 | Oral | 0 | 500 | MG | QD | ||||||||
| 127866511 | 12786651 | 10 | C | LOSARTAN POTASSIUM HCTZ | 2 | Oral | 0 | QD | |||||||||||
| 127866511 | 12786651 | 11 | C | SIMVASTATIN. | SIMVASTATIN | 1 | Oral | 0 | 10 | MG | QD | ||||||||
| 127866511 | 12786651 | 12 | C | GLIMEPIRIDE. | GLIMEPIRIDE | 1 | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 127866511 | 12786651 | 1 | Hypertension |
| 127866511 | 12786651 | 2 | Dyspepsia |
| 127866511 | 12786651 | 3 | Dyspepsia |
| 127866511 | 12786651 | 4 | Type 2 diabetes mellitus |
| 127866511 | 12786651 | 5 | Type 2 diabetes mellitus |
| 127866511 | 12786651 | 6 | Type 2 diabetes mellitus |
| 127866511 | 12786651 | 7 | Diuretic therapy |
| 127866511 | 12786651 | 8 | Pruritus |
| 127866511 | 12786651 | 9 | Diabetes mellitus |
| 127866511 | 12786651 | 10 | Ill-defined disorder |
| 127866511 | 12786651 | 11 | Blood cholesterol abnormal |
Outcome of event
| no results found |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 127866511 | 12786651 | Arthritis | |
| 127866511 | 12786651 | Blood glucose decreased | |
| 127866511 | 12786651 | Blood glucose increased | |
| 127866511 | 12786651 | Body height decreased | |
| 127866511 | 12786651 | Dyspepsia | |
| 127866511 | 12786651 | Fibromyalgia | |
| 127866511 | 12786651 | Intentional product misuse | |
| 127866511 | 12786651 | Pruritus | |
| 127866511 | 12786651 | Type 2 diabetes mellitus |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 127866511 | 12786651 | 4 | 201608 | 201608 | 0 | |
| 127866511 | 12786651 | 9 | 201603 | 0 |